Skip to main content
Clinical Trials/NCT01357460
NCT01357460TerminatedNot Applicable

Endoscopic Lung Volume Reduction in Patients With Advanced Emphysema Due to alpha1 Antitrypsin Deficiency

Heidelberg University1 site in 1 country18 target enrollmentStarted: May 1, 2011Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Terminated
Enrollment
18
Locations
1
Primary Endpoint
Improvement in pulmonary function (FEV1 (forced expiratory volume in 1 second) and RV/TLC (residual volume/total lung capacity)

Study Overview

Brief Summary

Patients with advanced heterogeneous emphysema due to alpha1 antitrypsin deficiency might benefit from endoscopic implantation of intrabronchial valves.

Detailed Description

Patient enrollment and data acquisition is to be carried out on a prospective basis. It is planned to enroll a total of 25 patients with advanced heterogeneous emphysema due to alpha1 antitrypsin deficiency. All patients will undergo treatment at one study centre in Heidelberg. Therapy of all patients consists of implantation of intrabronchial valves (IBV, Spiration, Olympus) in the most emphysematous destroyed lobe.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
30 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •pulmonary function: FEV1 < 45 %, RV > 150 %, TLC > 100 %
  • •alpha1 antitrypsin deficiency (< 80 mg/dl), genotype: PiZS, PiZZ, Pi0/0
  • •heterogenous emphysema

Exclusion Criteria

  • •homogenous emphysema
  • •significant bronchiectasis
  • •severe concomitant diseases
  • •pregnancy

Outcomes

Primary Outcomes

Improvement in pulmonary function (FEV1 (forced expiratory volume in 1 second) and RV/TLC (residual volume/total lung capacity)

Time Frame: 3 months

Secondary Outcomes

  • Average changes in pulmonary function (FEV1, VC (vital capacity), RV, TLC, RV/TLC)(3 months)
  • Average changes in 6-minute-walk-distance(3 months)
  • Evaluation of IBV migration rate(3 months)
  • Number of major complications(3 months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Felix JF Herth

Prof. Dr. med. Felix Herth

Heidelberg University

Study Sites (1)

Loading locations...

Similar Trials